BioAge Labs dosed the first participant in its Phase 2 trial of BGE-102 and plans to initiate a proof-of-concept trial for diabetic macular edema, signaling progress in its NLRP3 inhibition strategy.
BioAge Labs dosed the first participant in its Phase 2 trial of BGE-102 and plans to initiate a proof-of-concept trial for diabetic macular edema, signaling progress in its NLRP3 inhibition strategy.